This article is more than 5 years old. Information may no longer be current.

Stuart Watkins, MD, discusses the VERIFY-2 trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAS VEGAS — In this video, Stuart Watkins, MD, interventional cardiologist at Golden Jubilee National Hospital in Glasgow, Scotland, outlines the results of the VERIFY-2 trial, presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions.

The trial compared the use of instantaneous wave-free ratio (iFR) to Pd/Pa, or the ratio of distal coronary pressure to aortic pressure for the prediction of severity of coronary stenosis, in 97 patients with chest pain and standard indications for coronary angiogram. Both iFR and Pd/Pa are measured at rest, and neither require the administration of adenosine, unlike fractional flow reserve, the current gold standard.

Watkins said that the findings were consistent with those reported previously in the VERIFY and RESOLVE trials, and that no significant difference was observed in the accuracy of iFR vs. Pd/Pa while using a hybrid protocol or absolute binary cutoff. He concluded that iFR was no better than Pd/Pa for determining the significance of coronary stenosis, using FFR as a gold standard. Watkins added that the researchers do not feel that either nonhyperemic index is sufficiently accurate to guide revascularization in a cath lab.